

LECTURE SERIES & WORKSHOPS

INFECTION & IMMUNITY

21

MARCH 2019

Thursday

LECTURE

*Lycée Guillaume Kroll
d'Esch/Alzette
Salle de Projection **

9.00 am - 10.00 am


MEET & EAT *

light lunch provided
*House of BioHealth,
Room Françoise
Barré-Sinoussi*

10.30 am - 12.00 noon



*Please register sending a mail to florence.henry@lih.lu



SPEAKER

Prof Charles DINARELLO

Professor of Medicine and Immunology,
University of Colorado School of Medicine,
Professor of Experimental Medicine,
Radboud University, Netherlands

HOST:

**Department of Infection
and Immunity (LIH)**

RESPONSIBLE LIH SCIENTIST:

Dr Jacques Zimmer
(jacques.zimmer@lih.lu)

TREATING INFLAMMATION WITH IL-1 BLOCKADE FROM GOUT TO CANCER

ABSTRACT

Interleukin-1 (IL-1 α and IL-1 β) are highly active proinflammatory cytokines. Three IL-1-targeted agents have been approved: the IL-1 receptor antagonist (anakinra), a soluble decoy receptor (rilonacept), and a neutralizing monoclonal anti-interleukin-1 β antibody (canakinumab). In addition, a monoclonal antibody directed against IL-1 α is in clinical trials in cancer. Monotherapy blocking IL-1 β

IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity. A world-wide randomized placebo controlled trial in over 10,000 subjects of canakinumab revealed the pivotal role of IL-1 β in atherosclerosis, heart failure, gout, osteoarthritis and lung cancer. A randomized placebo controlled trial of anti-IL-1 α revealed the role of IL-1 α in cancer cachexia.

www.lih.lu

Supported by: